The role and potential efficacy of antithymocyte globulin (ATG) in patients receiving cord blood transplantation (CBT) remain controversial. We retrospectively evaluated the effect of ATG on patient outcomes in 207 children with high-risk or advanced hematological malignancies at 8 child blood disease centers in China. The cumulative incidence of platelet recovery on day 100 was significantly lower in the ATG cohort compared with the non-ATG cohort (77.3% versus 89.8%) (P ¼ .046). There was no significant difference in the incidence of grade II to IV acute and chronic graft-versus-host disease (GVHD), and transplantation-related mortality (TRM) between the 2 groups (P ¼ .76, P ¼ .57, and P ¼ .46, respectively). The incidence of CMV infection was significantly higher among the ATG group compared with that among the non-ATG group (P ¼ .003). The 5-year cumulative incidence of relapse was significantly higher in the ATG cohort (30.7% versus 15.4%) (P ¼ .009). Overall survival in the non-ATG group was slightly higher than that of the ATG cohort (64.1% versus 52.1%, P ¼ .093) and leukemia-free survival in the non-ATG cohort was significantly higher than in the ATG cohort (56.6% versus 37.7%, P ¼ .015). Our study demonstrated that, for high-risk or advanced childhood hematological malignancies receiving unrelated CBT, patients who received conditioning that omitted ATG had a faster platelet recovery, a comparable GVHD and TRM, a significantly lower relapse risk, and an improved long-term survival compared with those patients who received ATG in the conditioning.
INTRODUCTION
Acute graft-versus-host disease (GVHD) is the most important cause of death after allogeneic (allo) hematopoietic stem cell transplantation (HSCT), and antithymocyte globulin (ATG) has been used in the conditioning regimens to prevent the severe GVHD in this setting. Cord blood (CB) transplantation (CBT) is an effective and potential curative treatment for pediatric patients with hematological malignancies who lack HLA-identical related or unrelated donors. Several randomized controlled clinical trials reported that ATG-containing regimens lowered the risk of GVHD significantly compared with ATG-omitted regimens in the unrelated or mismatched allo-HSCT [1] [2] [3] [4] [5] . However, the role and potential efficacy of ATG in patients receiving CBT remains controversial. Most clinical studies demonstrated that incidence and severity of acute GVHD are lower in pediatric or adult CBT recipients compared with recipients of allo-HSCT from unrelated or mismatched donors [6] [7] [8] [9] [10] . This observation may be related to the 10-fold fewer T cells used in CBT and the predominantly naïve phenotype of CB T cells, which Biology of Blood and Marrow Transplantation j o u r n a l h o m e p a g e : w w w . b b m t . o r g have little baseline cytotoxicity and atypical functional properties [11] . However, the delayed T cell reconstitution after CBT can potentially lead to increased risk for severe infections, and this would be aggravated by the use of ATG as a regimen for the in vivo T cell depletion. Another concern about the use of ATG in CBT may be a decrease in the graftversus-leukemia (GVL) effect and an increase in the relapse incidence after transplantation due to the delayed immune reconstitution. In the present study, we retrospectively compared the outcomes of routine GVHD prophylaxis (cyclosporine-based regimens) plus pretransplantation ATG (ATG group) to routine GVHD prophylaxis alone (non-ATG group) in children with high-risk or advanced hematological malignancies receiving unrelated CBT.
PATIENTS AND METHODS

Patient Eligibility and Cord Blood Selection
The study included patients younger than 18 years at transplantation with hematological malignancies who received unrelated CBT between February 2000 and August 2013 at 8 child blood disease centers in China. These hematological malignancies included acute lymphoblastic leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia, and non-Hodgkin lymphoma, regardless of disease status at transplantation.
All of the childhood hematological malignancies patients who were referred for transplantation had at least 1 of the following high-risk features: (1) patients with acute leukemia were in first complete remission but have high-risk factors at first diagnosis, which we had been reported previously [12] ; that is, acute lymphoblastic leukemia with adverse cytogenetics or molecular abnormalities (ph þ chromosome [BCR-ABL positive], hypodiploidy, 11q23 abnormalities [mixed lineage leukemia {MLL} rearrangements]) or with a high level of minimal residual disease (1% or more after completion of 6 weeks of induction therapy); AML with adverse cytogenetics or molecular abnormalities (inv(3)(q21q26.2) or t(3;3)(q21;q26.2), t(6;9)(p23;q34), 11q23 abnormalities [MLL rearrangements], -5 or del(5q), -7 or del(7q), complex karyotype, normal cytogenetics with FLT3-ITD mutation), or prior history of MDS; (2) second complete remission or greater; (3) MDS-refractory anemia with excess blasts, juvenile myelomonocytic leukemia, chronic myeloid leukemia in accelerated phase or in blast crisis; or (4) primary induction failure or no remission after relapse with salvage chemotherapy (including non-Hodgkin lymphoma).
CBT was performed if no suitable related donor was available and the patients were regarded as having early transplantation without sufficient time for an unrelated bone marrow donor search. CB units that were serologically matched for ! 4 of 6 HLA antigens and which contained at least 3 Â 10 7 nucleated cells/kg and 1. In the non-ATG cohort (n ¼ 109), 107 (98.2%) patients received BUCY2-based (n ¼ 71, 65.2%) or TBICY-based (n ¼ 36, 33%) myeloablative conditioning. High-dose cytarabine, etoposide, fludarabine, melphalan, carmustine, or lomustine were added to the myeloablative conditioning regimen to kill the leukemia cells maximally, especially in extramedullary sites. For GVHD prophylaxis, all patients received cyclosporine A starting at 2.5 to 3 mg⁄kg intravenously daily on day À1 with target trough levels 200 to 250 ng/mL, or in combination with mycophenolate mofetil (25 to 30 mg/kg/day), methylprednisolone (1 mg/kg), or short-course methotrexate (7 to 15 mg/m 2 on day 1 and 7 to 10 mg/m 2 on days 3, 6, and/or 11), etc. Although the conditioning and GVHD prophylaxis regimens differed among the 8 centers, each center adhered to their own constant approaches throughout the study period.
Definitions and Statistical Analysis
Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count ! .5 Â 10 9 ⁄L and platelet engraftment was defined as the first day when the platelet count was ! 20 Â 10 9 ⁄L for 7 consecutive days without transfusion support. Primary graft failure was Data presented are n (%) unless otherwise indicated.
* Others include juvenile myelomonocytic leukemia (n ¼ 5), mixed acute leukemia (n ¼ 2), and MDS (n ¼ 1) in the ATG group, and juvenile myelomonocytic leukemia (n ¼ 1), mixed acute leukemia (n ¼ 2), MDS (n ¼ 2), and non-Hodgkin's lymphoma (n ¼ 1) in the non-ATG group.
y Others include MelþFlu (n ¼ 1), CYþFlu (n ¼ 1), TBIþMel (n ¼ 1) and TBIþMelþFlu (n ¼ 1) in the ATG group, and TBIþMelþFlu (n ¼ 2) in the non-ATG group.
defined as profound, persistent pancytopenia and marrow hypoplasia without donor-derived cells on day 42 or reconstitution with autologous cells. Both acute and chronic GVHD (aGVHD and cGVHD) were diagnosed and graded according to the previously published criteria [13, 14] . Transplantation-related mortality (TRM) was defined as death from any cause other than recurrent malignancy, and time to TRM was defined as the number of days from transplantation to death without preceding relapse.
Relapse was defined by the morphological evidence of disease in the peripheral blood, bone marrow, or extramedullary sites, and time to relapse was defined as the number of days from transplantation to the first diagnosis of relapse. Overall survival (OS) was defined as the number of days from transplantation to death of any cause, and leukemia-free survival (LFS) was defined as the number of days from transplantation to the first diagnosis of relapse or death. Variables of the 2 transplantation groups were compared via chi-square test (categorical covariates) or Mann-Whitney U-test (continuous covariates). Time-to-event outcomes for neutrophil and platelet engraftment, GVHD, TRM, and relapse were estimated using cumulative incidence curves, and these analyses were performed with R statistical software (R Foundation for Statistical Computing, Vienna, Austria) because of the presence of competing risks. For neutrophil or platelet engraftment and GVHD, death without an event was the competing risk; for TRM, relapse was the competing event, and for relapse, TRM was the competing event.
The probabilities of the OS and LFS were calculated using the Kaplan-Meier method, and these analyses were performed with SPSS (version 17.0). Differences at P < .05 were considered significant.
RESULTS
Engraftment and GVHD
Eighteen patients (8 in the ATG group and 10 in the non-ATG group) had primary graft failure. Rates of neutrophil engraftment were similar among ATG and non-ATG patients. The cumulative incidence of neutrophil recovery by day 42 was 91.2% (95% confidence interval [CI], 86.4% to 96.5%) in the ATG cohort and 90.8% (95% CI, 85.6% to 95.9%) in the non-ATG cohort (P ¼ .62). Patients achieved neutrophil engraftment in a median time of 17.2 days (range, 10 to 44) in the ATG group and 18.5 days (range, 9 to 37) in the non-ATG group (P ¼ .16). The cumulative incidence of platelet recovery on day 100 was significantly lower in the ATG cohort than in the non-ATG cohort (77.3% [95% CI, 68.6 to 86.3] versus 89.8% [95% CI, 82.9 to 94.2], P ¼ .046). These platelet engraftments occurred at 40.5 days (range, 17 to 91 days) and 38.5 days (range, 17 to 94 days) for the ATG and non-ATG patients, respectively ( Figure 1A) .
There was no difference in the incidence of aGVHD between the 2 groups. At day 100 after transplantation, the cumulative incidences of grade II to IV aGVHD in the ATG and non-ATG cohorts were 26.7% (95% CI, 19.6% to 33.2%) and 30.5% (95% CI, 24.8% to 36.5%), respectively (P ¼ .76). The cumulative incidences of severe aGVHD (grades III and IV) in the ATG and non-ATG cohorts were 13.3% (95% CI, 6.4% to 19.8%) and 14.6% (95% CI, 8.7% to 21.6%), respectively (P ¼ .83) ( Figure 1B) . Among patients who survived more than 100 days, the cumulative incidence of cGVHD (including local and extensive-type cGVHD) at 2 years after transplantation did not significantly differ between the ATG and the non-ATG cohorts (15.2% [95% CI, 10.6% to 20.8%] versus 18.3% [95% CI, 11.9% to 25.3%], P ¼ .57).
TRM and Relapse
Death from treatment-related complications occurred in 33 of 98 recipients of the ATG cohort, and in 30 of 109 recipients of the non-ATG cohort. TRM was not significantly different between the 2 groups: the cumulative incidence of TRM by day 180 was 32.1% (95% CI, 25.5% to 37.8%) and 28% (95% CI, 23.7% to 33.6%) in the ATG and non-ATG cohorts (P ¼ .46) (Figure 2A) . Bacterial or invasive fungal infection occurred in 44 patients (44.9%) in the ATG group and 39 patients (35.7%) in the non-ATG group (P ¼ .08). Fifty-four patients (55.1%) presented cytomegalovirus (CMV) infection and 12 (12.2%) with CMV disease in the ATG cohort, and 27 patients (24.8%) presented CMV infection and 9 (8.3%) with CMV disease in the non-ATG cohort. The incidence of CMV infection was significantly higher among the ATG group than in the non-ATG group (P ¼ .003). Twenty-three patients in the ATG group and 15 patients in the non-ATG group experienced leukemia relapse. The 5-year cumulative incidence of relapse was significantly higher in the ATG cohort when compared with that of the non-ATG cohort (30.7% [95% CI, 22.8% to 38.5%] versus 15.4% [95% CI, 10.9% to 20.6%], P ¼ .009) ( Figure 2B ). The causes of death were shown in Table 2 .
Survival
The median follow-up period among survivors was 39 months (range, 15 to 154) for the ATG group patients and 41 months (range, 16 to 152) for the non-ATG group patients Figure 1 . (A) Engraftment and acute GVHD. The cumulative incidence of neutrophil recovery by day 42 was 91.2% (95% CI, 86.4% to 96.5%) in the ATG cohort and 90.8% (95% CI, 85.6% to 95.9%) in the non-ATG cohort (P ¼ .62), and the cumulative incidence of platelet recovery on day 100 was significantly lower in the ATG cohort as compared with the non-ATG cohort (77.3% [95% CI, 68.6% to 86.3%] versus 89.8% [95% CI, 82.9% to 94.2%]) (P ¼ .046). (B) The cumulative incidences of grade II to IV aGVHD in the ATG and non-ATG cohorts were 26.7% (95% CI, 19.6% to 33.2%) and 30.5% (95% CI, 24.8% to 36.5%), respectively (P ¼ .76), and the cumulative incidences of severe aGVHD (grades 3 and 4) in the ATG and non-ATG cohorts were 13.3% (95% CI, 6.4% to 19.8%) and 14.6% (95% CI, 8.7% to 21.6%), respectively (P ¼ .83).
(P ¼ .82). The OS in the non-ATG group was slightly higher than in the ATG group, although the difference did not reach statistical significance: the 5-year OS for patients in the non-ATG group and in the ATG group was 64.1% (95% CI, 54.4% to 74.2%) and 52.1% (95% CI, 44.6% to 60.5%), respectively (P ¼ .093) ( Figure 3A) . The LFS in the non-ATG cohort was significantly higher than in the ATG cohort: the 5-year LFS for patients in the non-ATG cohort and the ATG cohort was 56.6% (95% CI, 46.5% to 66.8%) and 37.7% (95% CI, 31.7% to 43.9%), respectively (P ¼ .015) ( Figure 3B ).
DISCUSSION
The efficacy of ATG for GVHD prophylaxis in patients undergoing unrelated or mismatched allo-HSCT has been evaluated in several randomized controlled trials and the data indicated that ATG has a beneficial effect in preventing GVHD. Kumar et al. [15] performed a systematic review on the effect of ATG for the prevention of acute GVHD after related or unrelated allo-HSCT and found that ATG was effective in preventing grade III and IV aGVHD, but there was no improvement in TRM or survival. However, Soiffer et al. [16] examined 1676 adult patients with hematological malignancies undergoing reduced-intensity conditioning (RIC) transplantation from related or unrelated donors using fludarabine-based conditioning regimens, and the risk of acute GVHD was similar among patients who received either ATG or a T cellereplete HSCT. Lindemans et al. [17] recently first reported their retrospective comparative analysis to evaluate the role of ATG on immune reconstitution and clinical outcome in children undergoing unrelated CBT, and the data showed that children who underwent transplantation without ATG as part of their conditioning regimen experienced a remarkably quick immune reconstitution and significantly fewer viral reactivations, but also a higher probability of severe aGVHD compared with patients who received ATG; however, the cohort enrolled in the study was heterogeneous, including those with malignant and nonmalignant indications, the number of enrolled patients was relatively small, and the details of TRM and relapse of malignancies compared between ATG and non-ATG cohorts were not reported. The current study indicated that the cumulative incidence of neutrophil recovery at day 42 were similar between 2 groups, but the cumulative incidence of platelet recovery at day 100 was significantly lower in the ATG cohort than in the non-ATG cohort. Soiffer et al. [16] also reported that in sibling or unrelated RIC transplantation, the 28-day probabilities of neutrophil recovery were similar between recipients of ATGcontaining regimens (94%) and T cellereplete regimens (96%), but the day 60 probabilities of platelet recovery were lower with ATG-containing regimens (88%) compared with T cellereplete regimens (92%) (P ¼ .004). The ATG-Fresenius Trial Group [5] analyzed 202 patients with hematological malignancies undergoing unrelated allo-HSCT with and without ATG and found that the use of additional ATG resulted in delayed platelet engraftment: engraftment with platelets of 50 Â 10 9 /L or greater at day 100 was achieved in 68.0% of patients in the ATG-Fresnius group after a median of 37 days and in 84.7% in the control group (without ATG) after a median of 20 days (P < .0001). ATG can affect platelet aggregation and induce thrombocytopenia, and 1 study documented that patients treated with ATG in an allo-HSCT setting have an increased probability of developing more severe thrombocytopenia and need more platelet transfusions [18] . The polyclonal ATG contains antibodies specific to platelet glycoproteins V and IIa [18] and can be detected in the recipient's plasma up to 60 days after HSCT [17] . In this study, ATG patients also had significantly more CMV infections, which may affect platelet recovery. Nakamae et al. [19] found that active CMV infection was a significant risk factor for thrombocytopenia after day 28 in allo-HSCT (P ¼ .005), suggesting that active CMV infection was responsible for the delayed platelet recovery. On the other hand, T cells from the donor play an important role in facilitating stem cell engraftment in transplantation of CB, so we speculate that ATG's capacity to deplete donor T lymphocytes can affect platelet engraftment after CBT, and this phenomena might be obvious in the late use of ATG (days À5 to 0).
Our data showed that there was no difference in the incidence of aGVHD or cGVHD between the ATG and non-ATG cohort patients, suggesting that our CBT patients cannot obtain additional protection from ATG in terms of GVHD. The lower incidence and severity of acute GVHD after CBT might be attributed to the fewer nucleated cell dose and lower T cells allo-reactivity in CB [11] . Because of the concern of increased risk of infections or decreased disease control with ATG use, ATG administration is not a uniform practice in the CBT setting [20] . Although ATG was omitted in conditioning, Takahashi et al. [8, 21] reported that the cumulative incidences of grades III and IV aGVHD and extensive-type cGVHD among CBT recipients were significantly lower than those among related or unrelated bone marrow/peripheral blood stem cell transplant recipients, despite the higher HLA mismatching rate in CBT. Hagen et al. [22] retrospectively studied the effect of ATG in 144 AML patients (34 of whom received ATG) undergoing RIC CBT or HLA-matched sibling peripheral blood stem cell transplantations, and found that there were no differences in aGVHD and cGVHD between ATG and non-ATG patients. A more recent study [23] also showed that the omission of ATG before double CBT with RIC did not lead to an increased incidence of grade III and IV aGVHD (only 14%). However, in Lindemans's comparative analysis [17] , the aGVHD rate was higher in the non-ATG group: this might be influenced by the more selection of primary immunodeficiency patients in non-ATG group and the authors thought that such children would be at higher risk of aGVHD because of ongoing infections and tissue inflammation.
Although TRM was comparable between ATG and non-ATG cohorts, the incidence of CMV infection was significantly higher among the ATG group compared with that among the non-ATG group (P ¼ .003) in our study. Viral infections are a particular challenge after CBT because of the delayed immune reconstitution, which can be exacerbated by the use of ATG. Schaenman et al. [24] reported that the administration of ATG and total lymphoid irradiation resulted in a strikingly earlier viremia after transplantation when compared with the previously reported timing of viremia after myeloablative conditioning. The improved immune reconstitution in patients without ATG could lead to the lower incidence of virus reactivation after CBT. Lindemans et al. [17] found that the non-ATG group showed an early immune reconstitution and a lower number of episodes of viral reactivations compared with patients who received ATG. Sauter et al. [25] also reported that double unit CBT without ATG is associated with a prompt T cell recovery and a reduced incidence of Epstein-Barr virus and adenovirus infections compared with the published literature.
In the present study, the use of ATG significantly increases the likelihood of disease relapse (30.7% versus 15.4%, P ¼ .009), which negatively affects LFS (37.7% versus 56.6%, P ¼.015). More evidence indicated that cord bloodederived T cells were critical for the prevention of leukemic relapse, and the GVL effect may be increased over time as a result of thymic reconstitution after 3 to 6 months after CBT [11] . Lindemans et al. [17] indicated that the only predictor for early immune reconstitution after CBT was the omission of ATG from the conditioning regimen, and CD3 þ , CD4 þ , and CD4
þ -naïve T cell numbers were 1 log higher in the non-ATG group compared with the ATG group at 1, 2, 3, 6, and 12 months after CBT. ATG with the T cell depletion might contribute to a reduction in the GVL effect and an increase in the relapse incidence. Data from the Center for International Blood and Marrow Transplant Research [16] showed higher relapse rate and lower disease-free survival in patients who received alemtuzumab-containing (51% and 30%, respectively) and ATGcontaining (49% and 25%, respectively) regimens when compared with patients who received T cellereplete regimens (38% and 39%, respectively) (P <.001 and P <.001, respectively). Du et al. [26] conducted a systematic review and meta-analysis of ATG use in myeloablative HSCT, which included 10 clinical trials with a total of 1859 patients, and also showed that use of ATG with an increased incidence of leukemia relapse (relative risk, 1.28; P ¼ .04). The relationship between GVL and ATG is probably also dose dependent; that is, a higher ATG dose seems more effective in reducing the GVL effect compared with the lower dose. Remberger et al. [27] found, in patients receiving HLA-matched unrelated RIC-HSCT, that an ATG dose of 8 mg/kg resulted in a higher incidence of relapse and lower relapse-free survival compared with an ATG dose of 6 mg/kg (41% versus 19%, P ¼ .04; 61% versus 36%, P ¼ .14) and this effect was most apparent in patients with high-risk disease (54% versus 10%, P ¼ .02; 59% versus 23%, P ¼ .04). On the other hand, although ATG can remove and immobilize T cells and delay T cell recovery, some authors regarded that the decreased GVL effect caused by ATG can be overcome by increasing the infused cell dose and presumably by increasing the number of T cells. Remberger et al. [28] demonstrated that the ATG-treated patients receiving a nucleated cell dose ! 10 Â 10 8 /kg had a relapse incidence of 31% and relapse-free survival of 56%, compared with 83% (P ¼ .003) and 17% (P ¼ .05) in those receiving an nucleated cell dose <10 Â 10 8 /kg, in the context of RIC-HSCT from sibling donors.
In conclusion, the current study demonstrated that, for patients with high-risk or advanced childhood hematological malignancies receiving unrelated CBT, those whose conditioning omitted ATG had a comparable GVHD and TRM, a significantly lower relapse risk, and an improved long-term survival compared with those who received conditioning including ATG, and the omission of ATG was also associated with a faster platelet recovery and a lower rate of CMV infection. However, this was a nonprospective and nonrandomized study. The regimens used in the conditioning and GVHD prophylaxis are too heterogeneous, and whether or not to use ATG was also at the discretion of the each center. We strongly recommend conducting a prospective randomized clinical trial to evaluate whether the omission of ATG confers a survival advantage for children with hematological malignancies receiving unrelated CBT.
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